A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI in Individuals With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Treated With Intravesical Bacillus Calmette-Guerin (BCG)
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Tuberculosis vaccine (Primary)
- Indications Tuberculosis
- Focus Pharmacodynamics
- Acronyms RUTIVAC-1
- Sponsors Archivel Farma
- 09 Jan 2019 Status changed from suspended to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 29 Aug 2018 Planned End Date changed from 31 Aug 2019 to 31 Mar 2024.